Navigation Links
iCardiac's Highly Automated QT(sm) Technology Now Validated in Over 10 Clinical QT Studies
Date:2/5/2009

Validation Study Affirms Highly Automated Cardiac Safety ECG Analysis for Global Leader in Drug Development

Rochester, New York (PRWEB) February 5, 2009 -- iCardiac Technologies, Inc., a leading innovator in advanced cardiac safety biomakers and automated QT analysis, today announced the successful completion of a study for one of the world's leading pharmaceutical companies. The study validated the use of its Highly Automated QT(sm) technology to measure a full spectrum of ECG-based cardiac safety study data from mild to pronounced QT prolongation.

The study, performed with data from an existing compound, compared results from iCardiac's Highly Automated QT analysis with measurements performed independently by a large ECG core laboratory. The analysis was performed on data that included patients who ingested a placebo, moxifloxin (used as a positive control in cardiac safety studies), a normal and a supra-therapeutic dose of a study drug.

"This represents one of several validation studies of our technology with industry-leading drug developers," said iCardiac's Co-Founder and Executive Vice President Sasha Latypova. "To date our Highly Automated QT technology has been applied in over 10 clinical QT data analyses. Pharmaceutical companies are gaining more accurate results and are lowering substantially the cost per TQT study."

The study is part of iCardiac's broader validation program that aims at both reducing the cost of cardiac safety studies and developing the next generation of ECG biomarkers that are more predictive than the QT interval for characterizing arrhythmia risk associated with novel medicines.

The drive to automate more of the cardiac safety analysis process stems from general dissatisfaction in the industry regarding "gold standard" manual measurements that are both time-consuming and expensive. iCardiac's Highly Automated QT technology is different from "fully automated" approaches - which are based solely on computers - because it combines advanced ECG signal processing algorithms, developed over the past decade, with a robust quality assurance process conducted by cardiologists.

The technology performs a precise automated QT measurement and, using sophisticated statistical models and algorithms, guides cardiologists to those ECGs that require attention. It produces significant cost savings because only a portion of the entire Thorough QT (TQT) dataset requires manual over-reading.

Highly Automated QT analysis is part of iCardiac's software platform COMPAS 3.0, originally developed at the University of Rochester Heart Research Follow-Up Program, the international leader in electrophysiology research and the study of the congenital Long QT Syndrome. The platform provides comprehensive analysis of cardiac repolarization signals and contains several advanced arrhythmia biomarkers, as well as advanced ECG signal processing tools. The COMPAS platform serves as the core technology behind the leading cardiac safety analysis services that iCardiac provides to pharmaceutical, biotech companies and clinical research organizations.

About iCardiac Technologies
iCardiac Technologies, Inc. develops and implements advanced ECG-based cardiac safety biomarkers and tools. iCardiac's advanced ECG-based cardiac safety analysis service stems from more than 30 years of research at the University of Rochester, a leading institution for ventricular arrhythmias and cardiac repolarization. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement. In addition, it provides Beyond QT(sm), a suite of advanced ECG-based cardiac safety markers that deliver a more accurate assessment the cardiac safety profile of drugs in development. For more information, visit: www.icardiac.com.

###

Read the full story at http://www.prweb.com/releases/2009/02/prweb1957024.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Consumer Specialty Products Association Highly Critical of NRDC Study on Home Air Fresheners
2. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
3. 18F-DG PET/CT can highly increase the detection of colorectal cancer
4. Plastic Surgery Complications and Deaths are Rare, Despite Highly Publicized Death of Donda West
5. CT angiography highly accurate, multicenter trials show
6. CT Angiography Highly Accurate: Multicenter Trials Show
7. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
8. Highly Promising Dutch Research Into Alzheimers Disease and Parkinsons Disease
9. Songbirds offer clues to highly practiced motor skills in humans
10. LASIK works well, according to long-term study of highly myopic patients
11. Researchers find less invasive, highly accurate methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... ... financial consultations to communities in northern Virginia and DC, is announcing a cooperative ... for patients with Alzheimer’s and other disorders that lead to memory impairment. , ...
(Date:6/27/2017)... ... June 27, 2017 , ... Nearly 70 percent of ... released today by the American Society for Dermatologic Surgery (ASDS). , ... of consumers considering a cosmetic medical procedure has doubled since 2013. , “Cosmetic ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... for many of the health care industry’s hospitals and provider groups, has announced ... portal for select customers. Parasail Health is a San Francisco health-finance startup that ...
(Date:6/27/2017)... ... ... From June 20-22, EarQ and Widex held an exclusive training event ... is headquartered. , Together, the organizations educate hearing care professionals on how to ... latest in hearing technology. At the event, EarQ members got an in-depth look ...
(Date:6/27/2017)... ... June 27, 2017 , ... The Kelahan Agency, ... services to residents of southern New Hampshire, is teaming up with the New ... hunger and homelessness in the region. , New Horizons for New Hampshire provides ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... June 19, 2017  Researchers from DRUGSCAN ® ... will host a live, complimentary webinar titled, "Untangling methods ... to the real world" on Wednesday June 28, 2017 ... This webinar will feature interviews with recreational and ... the manipulation techniques abusers use to prepare opioid tablets ...
(Date:6/14/2017)... -- In 2016, Embodied Labs took top prize ... came away with $25,000 in seed-fund investment. Embodied Labs ... "entering the life of another" and by the Journal ... medical professionals in an entirely new dimension." Building upon ... for the Department of Education,s EdSimChallenge, where they received ...
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. ... focused on the design, manufacture, sale and distribution of ... on the progress of its commercial roll-out in ... available in more than one hundred (100) medical institutions ... AeroForm offers a needle-free alternative for women who ...
Breaking Medicine Technology: